Decreased appetite – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:35:06 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Decreased appetite – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of ART27.13 for Patients with Cancer-Related Anorexia and Weight Loss https://clinicaltrials.eu/trial/study-of-art27-13-for-patients-with-cancer-related-anorexia-and-weight-loss/ Wed, 29 Apr 2026 14:58:04 +0000 https://clinicaltrials.eu/trial/study-of-art27-13-for-patients-with-cancer-related-anorexia-and-weight-loss/ This clinical trial is focused on studying a condition known as Cancer Anorexia, which involves a loss of appetite and weight loss in patients with cancer. The trial is testing a new treatment called ART27.13, a synthetic cannabinoid, which is a man-made substance similar to chemicals found in the cannabis plant. The purpose of the study is to explore how effective ART27.13 is in helping patients gain weight, increase lean body mass, and improve their appetite and overall well-being.

Participants in the study will receive ART27.13 in the form of a hard capsule taken by mouth. Some participants may receive a placebo, which looks like the treatment but does not contain the active substance. The study will last for 12 weeks, during which the dose of ART27.13 may be gradually increased every four weeks for some patients. The study aims to observe changes in weight, appetite, and quality of life over this period.

The trial will also monitor the safety of ART27.13 by checking for any side effects and assessing the overall health of participants through regular medical tests and questionnaires. This research is important for understanding how ART27.13 can potentially help people with cancer who are experiencing significant weight loss and appetite issues.

]]>